Peter R Luijten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Peter R Luijten has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Bertine L. Stehouwer
Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands
1 shared publication - Dennis W. J. Klomp
Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publication - Maurice A. A. J. van Den Bosch
Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands
1 shared publication - Wybe J. M. van der Kemp
Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 27 October 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3 (1) , 634
Detection of alterations in membrane metabolism during neoadjuvant chemotherapy in patients with breast cancer using phosphorus magnetic resonance spectroscopy at 7 Tesla
Here we investigate the feasibility of tumor metabolism monitoring in T1c to T3 breast cancer during neoadjuvant chemotherapy by means of phosphorus (31P) magnetic resonance spectroscopy at 7 tesla (T). Five breast cancer patients were examined using a 31P MRSI sequence, prior to-, halfway-, and after neoadjuvant chemotherapy. The 31P MRSI data were analyzed on group and individual level and compared to a spectrum of a group of healthy volunteers. Ratios of phosphomonoesters (PME) to phosphodiesters (PDE) and phosphomonoesters to inorganic phosphate (Pi) were determined. Histopathologic assessment showed four partial responders and one complete responder to chemotherapy. The 31P spectrum of the patient group was distinctly different from the 31P spectrum of healthy volunteers and transformed its shape during the course of chemotherapy towards the shape of the spectrum of the healthy volunteers. Prior to chemotherapy the PME to PDE signal ratio and the PME to Pi signal ratio were high, and during the course of the chemotherapy these ratios normalized to the value of the healthy volunteers. Metabolite T2 values in tumor tissue tended to be lower than those for healthy glandular tissue. Assessment of individual patients showed that four out of five had a significant drop of the PME to Pi ratio by a factor of 2 or more. On average, the pH of the tumor, calculated from chemical shift variation of Pi, was 0.19 units lower before chemotherapy. We have demonstrated that the sensitivity of 31P MRSI in breast cancer at 7 T is sufficient to detect alterations in membrane metabolism during neoadjuvant chemotherapy, which may be used for early assessment of treatment efficacy.
- 27 October 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3 (1) , 634
Open AccessDetection of alterations in membrane metabolism during neoadjuvant chemotherapy in patients with breast cancer using phosphorus magnetic resonance spectroscopy at 7 Tesla
Here we investigate the feasibility of tumor metabolism monitoring in T1c to T3 breast cancer during neoadjuvant chemotherapy by means of phosphorus (31P) magnetic resonance spectroscopy at 7 tesla (T). Five breast cancer patients were examined using a 31P MRSI sequence, prior to-, halfway-, and after neoadjuvant chemotherapy. The 31P MRSI data were analyzed on group and individual level and compared to a spectrum of a group of healthy volunteers. Ratios of phosphomonoesters (PME) to phosphodiesters (PDE) and phosphomonoesters to inorganic phosphate (Pi) were determined. Histopathologic assessment showed four partial responders and one complete responder to chemotherapy. The 31P spectrum of the patient group was distinctly different from the 31P spectrum of healthy volunteers and transformed its shape during the course of chemotherapy towards the shape of the spectrum of the healthy volunteers. Prior to chemotherapy the PME to PDE signal ratio and the PME to Pi signal ratio were high, and during the course of the chemotherapy these ratios normalized to the value of the healthy volunteers. Metabolite T2 values in tumor tissue tended to be lower than those for healthy glandular tissue. Assessment of individual patients showed that four out of five had a significant drop of the PME to Pi ratio by a factor of 2 or more. On average, the pH of the tumor, calculated from chemical shift variation of Pi, was 0.19 units lower before chemotherapy. We have demonstrated that the sensitivity of 31P MRSI in breast cancer at 7 T is sufficient to detect alterations in membrane metabolism during neoadjuvant chemotherapy, which may be used for early assessment of treatment efficacy.